Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.41 is 25% above its 5-year average of -0.55, near the high end of its 5-year range (-1.31–-0.33).
5.13% below its 12-month average of -0.39.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.13.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.41
EARNINGS PER SHARE (EPS) AVG TTM
-0.39
EARNINGS PER SHARE (EPS) AVG 3Y
-0.36
EARNINGS PER SHARE (EPS) AVG 5Y
-0.55
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-5.13%
CURRENT VS 3Y AVG
-12.33%
CURRENT VS 5Y AVG
+25.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Compass Therapeutics, Inc.
Market Cap
$172.99M
Earnings Per Share (EPS)
-0.41
TTM Avg
-0.39
3Y Avg
-0.36
5Y Avg
-0.55
Market Cap
$173.04M
Earnings Per Share (EPS)
-1.02
TTM Avg
-0.60
3Y Avg
-1.87
5Y Avg
-1.57
Market Cap
$174.17M
Earnings Per Share (EPS)
-2.80
TTM Avg
-1.25
3Y Avg
-14.14
5Y Avg
-22.50
Market Cap
$176.96M
Earnings Per Share (EPS)
-27.00
TTM Avg
-15.00
3Y Avg
-27.00
5Y Avg
-32.85
Market Cap
$179.70M
Earnings Per Share (EPS)
-1.57
TTM Avg
-5.27
3Y Avg
-99.59
5Y Avg
-93.21
Market Cap
$162.82M
Earnings Per Share (EPS)
-1.13
TTM Avg
-2.24
3Y Avg
-2.81
5Y Avg
-2.43
Market Cap
$184.12M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.59
3Y Avg
-0.77
5Y Avg
-0.88
Market Cap
$153.84M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$192.97M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.66
3Y Avg
-3.05
5Y Avg
-5.28
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | $172.99M | -0.41 | -0.39 | -0.36 | -0.55 |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -1.02 | -0.60 | -1.87 | -1.57 |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -2.80 | -1.25 | -14.14 | -22.50 |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -27.00 | -15.00 | -27.00 | -32.85 |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | -1.57 | -5.27 | -99.59 | -93.21 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -1.13 | -2.24 | -2.81 | -2.43 |
| Journey Medical Corporation (DERM)vs › | $184.12M | -0.23 | -0.59 | -0.77 | -0.88 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -1.64 | -1.85 | -1.46 | -1.46 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -0.99 | -0.66 | -3.05 | -5.28 |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -0.26 | -0.53 | -0.57 | -0.55 |
Trailing EPS (TTM)
$-0.41
Forward EPS (Est.)
$-0.50
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.42 |
| 2024-12-31 | -0.36 |
| 2023-12-31 | -0.33 |
| 2022-12-31 | -0.35 |
| 2021-12-31 | -1.31 |
| 2020-12-31 | -0.52 |
| 2020-03-31 | -0.67 |
| 2019-03-31 | -7.66 |
